1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D7B72C9243D2EF02002585DC003E2FB5
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-managing-clinical-trials-during-beyond-covid-19-pandemic?opendocument
18
19opendocument
2044.201.97.138
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Clinical Operations » Clinical Trial Management

Best Practices for Managing Clinical Trials During and Beyond the COVID-19 Pandemic

ID: 5639


Features:

5 Info Graphics

14 Data Graphics

90 Metrics

26 Narratives


Pages/Slides: 30


Published: 2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Best Practices for Managing Clinical Trials During and Beyond the COVID-19 Pandemic”

The COVID-19 pandemic has altered clinical trials timelines and protocols for many pharmaceutical companies, but technological advancements have enabled savvy drug developers to make continued progress by switching many aspects of on-site clinical trials to virtual modes.

Best Practices, LLC conducted this benchmarking research to identify the best-in-class practices for managing clinical trials during the COVID-19 pandemic. This study examines the impact of COVID-19 pandemic on trials timelines, finances, data collection protocols, and staffing levels.

The study also
analyzes new trends in the management of virtual clinical trials, benefits of virtual clinical trials, and key learnings from industry leaders in managing clinical trials during COVID-19 and beyond.

Industries Profiled:
Medical Device; Biotech; Biopharmaceutical; Clinical Research; Pharmaceutical; Health Care; Computer Software; Telecommunications; Laboratories


Companies Profiled:
Alcon; Alnylam Pharmaceuticals; Aptus Clinical; Atara Biotherapeutics; Cipla; CSL Behring; Cytiva; Idorsia; Kyowa Kirin; MedinCell; Merck; Novartis; Ora; Inc.; Sanofi; United BioSource

Study Snapshot

Best Practices, LLC engaged 18 leaders from 15 life science organizations in this research through a benchmarking survey. More than half of the research participants serve at the director or executive level.

Key topics covered in this research include:

  • Impact of COVID-19 Pandemic on Clinical Trials
  • Virtual Clinical Trials
  • Clinical Trial Data Collection
  • Benefits of Virtual Clinical Trials
  • Staffing Changes During the Pandemic
  • Key Learnings on Managing Trials During the Pandemic


Key Findings

Select key insights uncovered from this research are noted below. Detailed findings are available in the full study.

  • Delay in Clinical Trials: Many companies have delayed clinical trials by 3 to 6 months. About 2 in 10 trials have halted completely.

  • Enrolment: Companies are enrolling patients through registration links sent over email and video calls. Some companies have also built an app to improve patient enrolment.


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.